OBJECTIVES
 A ClinicalTrials.gov database search was performed by applying the categories country, study type, and indication.  All retrospective studies were excluded from the search, focusing on the study type "observational" with all recruitment conditions (e.g. not yet recruiting, recruiting, completed).  Studies of the last ten years (06/2008 until 06/2018) were included, if they were conducted in the following European countries: Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Spain, Sweden, and the United Kingdom (UK).  The influence of the population and pharmaceutical market size as well as different regulatory requirements in each country were considered when interpreting the results.  Furthermore, out of about 2,000 diseases the top five in the respective country were investigated.
METHODS
 The countries could be categorized into two clusters with (1) the populous countries (Germany, France, UK, Italy and Spain) and (2) the Northern countries and Benelux.  The proportion of RWE studies in relation to the number of overall prospective studies ranged from 13.0% in Spain to 41.3% in Luxembourg.  This order of the two clusters changed when taking the population size of each investigated country [2] into account. Denmark, followed by Norway and Belgium had the highest proportion of RWE studies in relation to the population size (16.9 studies per 100,000 inhabitants in Denmark, 8.3 studies per 100,000 inhabitants in Norway, and 7.4 studies per 100,000 inhabitants in Belgium). Spain, Italy and the UK were at the rear ranks with 2.2 studies per 100,000 inhabitants in Spain, 2.3 studies per 100,000 inhabitants in Italy, and 2.6 studies per 100,000 inhabitants in the UK.  Considering also the pharmaceutical market value of each country [3], which highly correlates with the population size (r=0.991, p<0.001), a similar ranking with the two clusters of countries could be observed (see Table 1 ).
 Regarding the regulatory requirements and guidelines of the European countries, some countries have very detailed regulations whereas others have hardly no legislation at all. In some countries an approval, registration and/or notification of the competent authority, ethic committee as well as data protection agency is required whereas in others, the official notification to these authorities is not necessary.  Finland, Germany, and Italy were the countries with the highest number of institutions which have to be informed, followed by Belgium, Luxembourg, Spain, Sweden, and UK whereas Denmark, France, the Netherlands, and Norway had less regulations concerning the notification process.  Concerning the investigated diseases in the RWE studies, vascular and heart diseases as well as respiratory tract diseases were among the top five diseases in most of the countries (see Figure 3) .
 Prospective RWE studies still play a minor role in the pharmaceutical research in contrast to clinical trials.  Large differences in the total number of registered prospective RWE studies was observed across the included European countries. The Nordic countries as well as Belgium and the Netherlands have lower numbers of RWE studies whereas in relation to country size and pharmaceutical market value, the number rises showing the importance of this study type in these regions.  In addition, the proportion of RWE studies on the overall prospective studies varied between the nations.  Furthermore, the regulatory requirements strongly depend on the respective country, and the interactions between requirements and pharmaceutical markets should be studied in more detail.  Vascular and heart diseases as well as respiratory tract diseases are currently of interest within prospective RWE research.
CONCLUSIONS
 Possibly not all studies have been accounted for as not all clinical trials and RWE studies might be registered in this database.  The diseases reported in the database partly overlap so that a distinct calculation of the top 5 was not possible. Furthermore, only pre-defined diseases instead of aggregated disease categories were analyzed. N: Number of studies in the respective disease; Note: In some of the countries, the number of studies in the top 5 ranking was the same (e.g. Luxembourg N=5).
LIMITATIONS Figure 3. Top 5 Diseases in Prospective RWE Studies Stratified by European Country

